PT  - JOURNAL ARTICLE
AU  - Zenner, Kaitlyn
AU  - Jensen, Dana M.
AU  - Dmyterko, Victoria
AU  - Shivaram, Giridhar M.
AU  - Myers, Candace T.
AU  - Paschal, Cate R.
AU  - Rudzinski, Erin R.
AU  - Pham, Minh-Hang M.
AU  - Cheng, V. Chi
AU  - Manning, Scott C.
AU  - Bly, Randall A.
AU  - Ganti, Sheila
AU  - Perkins, Jonathan A.
AU  - Bennett, James T.
TI  - Somatic activating <em>BRAF</em> variants cause isolated lymphatic malformations
AID  - 10.1101/2021.11.03.21265682
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.03.21265682
4099  - http://medrxiv.org/content/early/2021/11/05/2021.11.03.21265682.short
4100  - http://medrxiv.org/content/early/2021/11/05/2021.11.03.21265682.full
AB  - Somatic activating variants in PIK3CA, the gene that encodes the p110α catalytic subunit of PI3K, have been previously detected in ∼80% of lymphatic malformations (LM).1; 2 We report the presence of somatic activating variants in BRAF in individuals with PIK3CA-negative LM. The BRAF substitution p.Val600Glu (c.1799T>A), one of the most common driver mutations in cancer, was detected in multiple individuals with LM. Histology revealed abnormal lymphatic channels with immunopositivity for BRAFV600E in endothelial cells that was otherwise indistinguishable from PIK3CA positive LM. The finding that BRAF variants contribute to low-flow LMs increases the complexity of prior models associating low flow vascular malformations (LM and venous malformations) with mutations in the PI3K-AKT-MTOR and high flow vascular malformations (arteriovenous malformations) with mutations in the RAS-MAPK pathway.3 Additionally, this work highlights the importance of genetic diagnosis prior to initiating medical therapy as more studies examine therapeutics for individuals with vascular malformations.Competing Interest StatementR. A. Bly: Co-founder EigenHealth, Inc, Consultant to SpiWay, LLC. Dr. Randall Bly holds a financial interest of ownership equity with Wavely Diagnostics, Inc. The remaining authors have declared that no conflict of interest exists.Funding StatementThis study was funded by the US National Institutes of Health under National Heart, Lung, and Blood Institute (NHLBI) grants F32HL147398 and R01 HL130996, as well as a Burroughs Wellcome Career Award for Medical Scientists 1014700 and a Seattle Childrens Hospital Guild Association Funding Focus Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board at Seattle Childrens HospitalI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors